chr22-50221071-A-C
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 2P and 9B. PM2BP4_StrongBP6BS1
The NM_020461.4(TUBGCP6):āc.3288T>Gā(p.Asp1096Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000661 in 1,528,310 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_020461.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TUBGCP6 | NM_020461.4 | c.3288T>G | p.Asp1096Glu | missense_variant | 16/25 | ENST00000248846.10 | NP_065194.3 | |
TUBGCP6 | XR_001755343.3 | n.3852T>G | non_coding_transcript_exon_variant | 16/20 | ||||
TUBGCP6 | XR_938347.3 | n.3852T>G | non_coding_transcript_exon_variant | 16/23 | ||||
TUBGCP6 | XR_007067982.1 | n.3048+957T>G | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TUBGCP6 | ENST00000248846.10 | c.3288T>G | p.Asp1096Glu | missense_variant | 16/25 | 1 | NM_020461.4 | ENSP00000248846 | P1 | |
TUBGCP6 | ENST00000439308.6 | c.3288T>G | p.Asp1096Glu | missense_variant | 16/25 | 1 | ENSP00000397387 | |||
TUBGCP6 | ENST00000498611.5 | n.3617+204T>G | intron_variant, non_coding_transcript_variant | 1 | ||||||
TUBGCP6 | ENST00000491449.5 | n.1595T>G | non_coding_transcript_exon_variant | 8/16 | 5 |
Frequencies
GnomAD3 genomes AF: 0.000447 AC: 51AN: 114020Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000717 AC: 18AN: 251208Hom.: 0 AF XY: 0.0000589 AC XY: 8AN XY: 135802
GnomAD4 exome AF: 0.0000346 AC: 49AN: 1414204Hom.: 0 Cov.: 37 AF XY: 0.0000298 AC XY: 21AN XY: 704372
GnomAD4 genome AF: 0.000456 AC: 52AN: 114106Hom.: 0 Cov.: 33 AF XY: 0.000416 AC XY: 23AN XY: 55318
ClinVar
Submissions by phenotype
Microcephaly and chorioretinopathy 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Aug 11, 2021 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 07, 2023 | This sequence change replaces aspartic acid, which is acidic and polar, with glutamic acid, which is acidic and polar, at codon 1096 of the TUBGCP6 protein (p.Asp1096Glu). This variant is present in population databases (rs6010209, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with TUBGCP6-related conditions. ClinVar contains an entry for this variant (Variation ID: 966787). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The glutamic acid amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | May 09, 2023 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at